Click here for Analysts' Upgrades, Downgrades.
Editor's Note: Green and red arrows refer to intraday stock price movement.
NEW YORK (
STOCK COMMENTS / EPS CHANGES
price target was raised at Bank of America/Merrill Lynch to $38 from $34 on better-than-expected third-quarter results. Maintain Buy rating.
estimates, target raised at Morgan Stanley. Shares now seen reaching $70, according to Morgan Stanley. Estimates also increased, given higher expected growth across the board. Overweight rating.
price target upped at Morgan Stanley to $105.
( BUCY) deal should be accretive to earnings. Overweight rating.
estimates lowered at Oppenheimer through 2011. Company is buying back less stock and seeing lower net earned premiums. Outperform rating and $66 price target.
estimates increased through 2012 at Morgan Stanley. Company is seeing better credit trends. Equal-weight rating and $46 price target.
estimates, target raised at Jefferies. Shares now seen reaching $120. Estimates also increased, as the company should continue to see higher billings. Hold rating.
El Paso Electric
numbers boosted at Jefferies. Shares of EE now seen reaching $30.50, according to Jefferies. Estimates also upped, as the utility should see rate increases in the near future. Buy rating.
estimates raised through 2013 at Goldman Sachs. Company is positioned to benefit from a strong generic pipeline. Neutral rating and $54 price target.
estimates, target boosted at UBS. Shares now seen reaching $15. Estimates also upped, given an improving growth outlook. Buy rating.
( FTO) estimates reduced at Oppenheimer through 2011. Refining environment remains weak and the company saw downtime at its Cheyenne refinery. Perform rating.
target upped at Argus to $48. Company can continue to grow in the international markets, Argus said. Buy rating.
2011 and 2012 EPS estimates raised at Barclays to $1.95 and $2.20, respectively. Solid third-quarter results with strong sales and margins, Barclays said. Maintain Overweight rating and $36 price target.
price target boosted at Bank of America/Merrill Lynch to $54 from $49 ahead of first-quarter 2011 results, which are expected to be strong. Maintain Buy rating.
estimates, target boosted at Goldman Sachs.Shares now seen reaching $43. Estimates also upped, as the company is realizing higher margins. Neutral rating.
estimates raised at Goldman Sachs through 2012. Company received favorable securitization pricing, Goldman said. Neutral rating and $32 price target.
estimates raised at Barclays. The company's 2011 and 2012 EPS estimates raised to $1.43 and $1.65, respectively. Soft demand, smooth execution, Barclays said. Maintain Neutral rating and $26 price target.
Lowe's estimates, target raised at Citigroup. Shares now seen reaching $23. Estimates also increased, as the company is realizing higher gross margins. Hold rating.
estimates increased through 2012 at Goldman Sachs. Company remains leveraged to increased growth in generic drugs. Buy rating and $68 price target.
price target raised at Barclays to $20. Expecting solid third-quarter results and in-line guidance, Barclays said. Maintain Equal Weight rating.
estimates raised at Bank of America/Merrill Lynch.2010, 2011 and 2012 EPS estimates increased to $1.53, $1.06, and $1.01, respectively. Potential market share gains, Bank of America/Merrill Lynch said. Maintain Buy rating and $33 price target.
numbers boosted at Keybanc. Shares of SIAL now seen reaching $74, according to Keybanc. Estimates also upped, as the company continues to generate solid organic growth. Buy rating.
price target raised at Barclays to $85 from $66 following strong fourth-quarter results. Reiterate Overweight rating.
estimates upped at Goldman Sachs through 2013. Company is likely seeing higher demand from small-business customers. Sell rating and $38.50 price target.
estimates increased through 2012 at Goldman Sachs. Company is opening more stores and seeing lower tax rates, Goldman said. Neutral rating and $33 price target.
This article was written by a staff member of TheStreet.